New study matches melanoma patients to drugs based on their Tumor's genes

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for Part 1: 1. Written informed consent for Part 1 2. Newly diagnosed, histologically confirmedand , unresectable Stage IIIB, IIIC or Stage IV melanoma including cutaneous (including acral, ungual subtypes), ocular (including uveal and extra-uveal), mucosal, and unknown primary). 3. Treatment-naïve for unresectable advanced orf metastatic melanoma (systemic treatment given in the neoadjuvant and adjuvant settings are acceptable). 4. Tumour tissue available from advanced or metastatic disease. Archival tissue from primary or regional recurrent melanoma may be considered if no recent sample is available. 5. Male or female patients aged 18 or over. 6. Standard of care molecular tumour testing which has identified NRAS wild type, and either BRAF wild type or non-V600 BRAF mutant melanoma. 7. Adequate tissue available for the Molecular Testing Platform. Eligibility Criteria for NGS Molecular Testing Platform (Part 1) 1. Standard of care molecular tumour testing which has identified non V600 BRAF or BRAF wild type, or NRAS wild type melanoma (NRAS mutant patients are eligible for Part 2, but will not undergo NGS testing). 2. Adequate tissue available per NGS specimen preparation instructions. Inclusion Criteria for Part 2: 1. Written informed consent to receive targeted therapy (if applicable) and clinical follow up. 2. Patient has undergone NGS tumour testing or has NRAS or ALKati mutant melanoma on routine testing 3. Histologically confirmed melanoma of any sub type with measurable disease per RECIST criteria. 4. Received available standard therapies or clinical trial agents for unrectable metastatic melanoma that has progressed, unable to tolerate standard therapy, or standard therapy is contraindicated. 5. Patient has an 'actionable' genetic aberration and matched targeted therapy is available. Patients with no genetic aberration or where no matched targeted therapy is available, patients will be offered trametinib 6. ECOG status 0 - 2. 7. Adequate haematological, hepatic and renal organ function as defined by: 1. White cell count ≥ 2.0 × 109/L 2. Neutrophil count ≥ 1.5 × 109/L 3. Haemoglobin ≥ 90 g/L 4. Platelet count ≥ 100 x 109/L 5. Total bilirubin ≤ 3.0 x ULN 6. Alanine transaminase ≤ 3.0 x ULN 7. Aspartate aminotransferase ≤ 3.0 x ULN 8. Serum creatinine ≤ 1.5 x the upper limit of normal (ULN). 8. Life expectancy \> 30 days. 9. Women of child bearing potential (WOCBP) to use contraception to avoid pregnancy. 10. Non sterile men with female partners of CBP to use contraception to avoid pregnancy. Exclusion criteria for Matched Targeted Therapy: 1. An expectation for the need for concurrent radiotherapy (unless safety has been established with the matched drug regimen and is directed at one anatomical region for symptom control). 2. Any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug. 3. Any investigational drug or other systemic drug therapy for melanoma within 14 days or 5 half-lives from baseline, whichever is shorter. 4. Pregnant or breast feeding females. 5. Drug specific exclusions as detailed in the TGA Product Information for each drug.